Rystiggo (rozanolixizumab) receives approval in Japan for two new administration methods for people living with generalized Myasthenia Gravis – UCB
UCB announced that it has received approval from the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan for at-home self-administration with infusion pump or a new manual push… read more.
